Further to the update shared on 5 August 2019. As you will be aware the company (Aegerion Pharmaceuticals) requested reconsideration of this topic in line with the HST Interim Methods and Process guide, to undertake further work to address the concerns outlined by the committee. This request has now been granted to enable the company to prepare and provide further evidence for committee’s consideration.
NICE will formally invite participating stakeholders to provide evidence submission on 5 March 2020. The HST committee will consider the evidence submitted at the HST committee meeting on 8 October 2020.